BY MARKETWIRE
-
Pfizer offloads Haleon shares worth GBP 2.5bn
Haleon produces various over-the-counter health products and medicines.
-
Citi predicts surpise doubling in sales of Eli Lilly’s obesity drug
Based upon residential prescription information, the significant United States financial institution is currently elevating its sales projection for both Zepbound for excessive wei…
-
Genmab reports promising data in ovarian and pelvic cancer treatment study
” The upgraded outcomes enhance the capacity of Rina-S and additional confirm our advancement strategy in innovative ovarian cancer cells,” claims Genmab’s Princi…
-
AstraZeneca acquires Belgian biotech company in potential USD 1bn deal
The pharmaceutical group pays USD 425m upfront to acquire Belgian Esobiotec.
-
AstraZeneca acquires Belgian biotech company in potential USD 1bn deal
The pharmaceutical group pays USD 425m upfront to acquire Belgian Esobiotec.
-
Lundbeck drug receives EU approval for treatment of schizophrenia in adolescents
Rexulti was authorized in 2018 for the therapy of schizophrenia in grownups.
-
Ambu could be heading into a year of billion-kroner acquisitions
Nordea approximates that the Danish medtech team can conveniently allot DKK 5bn this year for purchases without unneeded stress on the annual report,
-
Trade association opposes FDA decision to remove weight-loss drugs from shortage list
Novo Nordisk requires that business quit marketing unlawful duplicates, presumably presenting a severe threat to individuals.
-
Lundbeck drug receives EU approval for treatment of schizophrenia in adolescents
Rexulti was approved in 2018 for the treatment of schizophrenia in adults.
-
Trade association opposes FDA decision to remove weight-loss drugs from shortage list
Novo Nordisk demands that companies stop selling illegal copies, allegedly posing a serious risk to patients.
